AT
Alchemab Therapeutics
United Kingdom · Biotech
Alchemab Therapeutics develops antibody medicines by studying people resilient to disease.
Product
Alchemab Therapeutics is a UK biotechnology company discovering protective antibodies in people who show resilience to disease. Its Resiliome platform combines antibody sequencing, AI and laboratory validation to identify candidates for new medicines.
Founded in 2019, the company develops treatments for conditions with substantial unmet need. Its research draws on a large proprietary antibody database and has produced ATLX-1282, an amyotrophic lateral sclerosis antibody therapeutic licensed to Eli Lilly.
Funding history
5 rounds · 4 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A extension | £25M | British Business Bank — Participant | |
| Parkinson research grant | $595K | The Michael J. Fox Foundation for Parkinson's Research — Participant | |
| Biomedical Catalyst grant | £1.7M | Innovate UK — Participant | |
| Series A | £60M | RA Capital Management — LeadDCVC — ParticipantDementia Discovery Fund — ParticipantDHVC — ParticipantLightstone Ventures — ParticipantSV Health Investors — Participant | |
| Biomedical Catalyst grant | Undisclosed | Innovate UK — Participant |
Investors
British Business BankJoined Series A extensionThe Michael J. Fox Foundation for Parkinson's ResearchJoined Parkinson research grantInnovate UKJoined Biomedical Catalyst grant · Joined Biomedical Catalyst grantRA Capital ManagementLed Series ADCVCJoined Series ADementia Discovery FundJoined Series ADHVCJoined Series ALightstone VenturesJoined Series ASV Health InvestorsJoined Series ACoverage
weeklyWeekly funding picks, July 6–12: lithium offtake, grid flexibility and antibody researchJul 9, 2026Alchemab Therapeutics · Series A extensionJun 6, 2024Alchemab Therapeutics · Parkinson research grantDec 16, 2022Alchemab Therapeutics · Biomedical Catalyst grantSimilar companies
SSSunlit SeedlingsSunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.Undisclosed · Corporate investment
BiomatterBiomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.$18M · Series A
OOOrakl OncologyCombines patient-derived tumour organoids, clinical data and AI to help pharmaceutical companies develop cancer treatments.$34M · Series A